# Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

> **NCT07203755** · PHASE1 · RECRUITING · sponsor: **CanSino Biologics Inc.** · enrollment: 260 (estimated)

## Conditions studied

- Diphtheria, Tetanus and Acellular Pertussis
- Epidemic Meningitis
- Haemophilus Influenzae Type B Infection

## Interventions

- **BIOLOGICAL:** Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)
- **BIOLOGICAL:** DTcP-Hib-MCV4
- **BIOLOGICAL:** DTcP-Hib-MCV4
- **BIOLOGICAL:** DTcP-Hib-MCV4
- **BIOLOGICAL:** DTcP-Hib-MCV4
- **BIOLOGICAL:** Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)
- **BIOLOGICAL:** Haemophilus influenzae type b (Conjugate) (Hib)
- **BIOLOGICAL:** Meningococcal Group ACYW135 (Conjugate) (MCV4)
- **BIOLOGICAL:** MCV4
- **BIOLOGICAL:** MCV4
- **OTHER:** Sodium Chloride Injection (0.9%) (Saline Solution) (NS)

## Key facts

- **NCT ID:** NCT07203755
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07203755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07203755, "Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07203755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*